How Biotech Cos. Can Utilize Synthetic Royalty Financing

By Todd Trattner and Ryan Murr (February 1, 2024, 5:31 PM EST) -- Following the capital markets boom fueled by the Fed's accommodating monetary policy in 2020 and 2021, the biotech sector suffered nearly a 50% drop over a 12-month period from February 2021 to February 2022, and has generally traded flat, with some dips and spikes, since then through the end of 2023.[1]...

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.

A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!